| 7th Jul 2020 8:00 am |
RNS |
Holding(s) in Company |
| 7th Jul 2020 7:00 am |
RNS |
Notification of Dilution of Voting Rights |
| 29th Jun 2020 7:00 am |
RNS |
Blocklisting Six Monthly Return |
| 26th Jun 2020 7:00 am |
RNS |
Notice of Results |
| 25th Jun 2020 7:15 am |
RNS |
$100 Million Equity Investment by General Atlantic |
| 18th Jun 2020 8:15 am |
RNS |
Fruquintinib Granted US FDA Fast Track Designation |
| 9th Jun 2020 7:00 am |
RNS |
US$95m Guangzhou Land Compensation Agreement |
| 4th Jun 2020 7:00 am |
RNS |
Continuation of Phase III FRUTIGA Study |
| 2nd Jun 2020 4:40 pm |
RNS |
Second Price Monitoring Extn |
| 2nd Jun 2020 4:37 pm |
RNS |
Price Monitoring Extension |
| 1st Jun 2020 7:00 am |
RNS |
Chi-Med Plans to Submit US NDA for Surufatinib |
| 29th May 2020 1:00 pm |
RNS |
Chi-Med to Discuss Data Presented at ASCO20 |
| 29th May 2020 7:00 am |
RNS |
NDA Acceptance in China for Savolitinib |
| 26th May 2020 7:00 am |
RNS |
Chi-Med and BeiGene Enter Clinical Collaboration |
| 14th May 2020 7:00 am |
RNS |
Clinical Data to be Presented at ASCO20 |
| 11th May 2020 4:41 pm |
RNS |
Second Price Monitoring Extn |
| 11th May 2020 4:36 pm |
RNS |
Price Monitoring Extension |
| 11th May 2020 7:00 am |
RNS |
Chi-Med to Attend Upcoming Investor Conferences |
| 29th Apr 2020 11:45 am |
RNS |
Grant of Share Options under Share Option Scheme |
| 27th Apr 2020 2:00 pm |
RNS |
Result of AGM |
| 22nd Apr 2020 9:00 am |
RNS |
Virtual Presentations of Surufatinib at AACR |
| 21st Apr 2020 11:30 am |
RNS |
Grant of LTIP Awards and Share Options |
| 17th Apr 2020 7:00 am |
RNS |
Surufatinib Granted FDA Fast Track Designations |
| 31st Mar 2020 7:04 am |
RNS |
China Phase II trial initiation in mesothelioma |
| 25th Mar 2020 7:00 am |
RNS |
Annual Financial Report |
| 9th Mar 2020 7:00 am |
RNS |
Vesting of awards under Long Term Incentive Plan |
| 3rd Mar 2020 2:18 pm |
RNS |
Form-20F Publication |
| 3rd Mar 2020 12:15 pm |
RNS |
Final Results and Clinical Update |
| 25th Feb 2020 7:00 am |
RNS |
Notice of Results |
| 10th Feb 2020 7:00 am |
RNS |
Phase II Savolitinib / Imfinzi® Combination Data |
| 6th Feb 2020 4:35 pm |
RNS |
Price Monitoring Extension |
| 6th Feb 2020 7:20 am |
RNS |
Issue of Equity |
| 4th Feb 2020 4:40 pm |
RNS |
Second Price Monitoring Extn |
| 4th Feb 2020 4:35 pm |
RNS |
Price Monitoring Extension |
| 31st Jan 2020 7:00 am |
RNS |
Notice of Results |
| 29th Jan 2020 7:25 am |
RNS |
Holding(s) in Company |
| 23rd Jan 2020 7:35 am |
RNS |
Pricing of US$110 Million Public Offering of ADSs |
| 22nd Jan 2020 7:00 am |
RNS |
Chi-Med Announces Proposed Offering of ADSs |
| 20th Jan 2020 10:40 am |
RNS |
Positive SANET-p Phase III Clinical Trial Results |
| 13th Jan 2020 7:00 am |
RNS |
Chi-Med Starts Surufatinib+PD-1 Ph2 Combo Trial |
